NCT02867709: A reported trial by Allergan
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02867709 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 26, 2016 |
| Completion date | Jan. 25, 2018 |
| Required reporting date | Jan. 25, 2019, midnight |
| Actual reporting date | Jan. 9, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |